search
Back to results

Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Primary Purpose

Opioid-Induced Constipation (OIC)

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
NKTR-118
Usual care
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opioid-Induced Constipation (OIC) focused on measuring Non-Cancer-Related Pain, Opioid-Induced Constipation

Eligibility Criteria

18 Years - 84 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Provision of written informed consent prior to any study-specific procedures.
  • NEW PATIENTS ONLY: Self-reported active symptoms of OIC at screening (<3 SBMs/week and experiencing >1 reported symptom of hard/lumpy stools, straining, or sensation of incomplete evacuation/anorectal obstruction in at least 25% of the BMs over the previous 4 weeks); and Documented confirmed OIC (<3 SBMs/week on average over the 2-week OIC confirmation period.
  • PATIENTS ENROLLING FROM OTHER NKTR-118 STUDIES: Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg or oral morphine, or equianalgesic amount(s) of 1 or more opioid therapies.
  • FOR PATIENTS RANDOMIZED TO RECEIVE NKTR-118: Willingness to stop all laxatives and other bowel regimens including prune juice and herbal products throughout the 52-week treatment period, and to use only bisacodyl as rescue medication if BM has not occurred within at least 72 hours of the last recorded BM.

Exclusion Criteria:

  • Patients receiving Opioid regimen for treatment of pain related to cancer.
  • History of cancer within 5 years from first study visit with the exception of basal cell cancer and squamous cell skin cancer.
  • Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.
  • Other issues related to the gastrointestinal tract that could impose a risk to the patient.
  • Pregnancy or lactation.

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

Oral Treatment

Oral treatment

Outcomes

Primary Outcome Measures

Incidence of Patients Experiencing at Least One Adverse Event (AE)
The incidence of patients experiencing at least one AE during the randomized treatment and follow-up periods was calculated.
Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)
The incidence of patients experiencing AEs that resulted in discontinuation of IP during the randomized treatment or follow-up periods was calculated.
Incidence of Patients Experiencing Severe Adverse Events (SAEs)
The incidence of patients experiencing SAEs during the randomized treatment and follow-up periods was calculated.

Secondary Outcome Measures

Full Information

First Posted
April 14, 2011
Last Updated
October 13, 2014
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT01336205
Brief Title
Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
Official Title
An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain
Study Type
Interventional

2. Study Status

Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
April 2011 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
December 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the long-term safety and tolerability of NKTR-118 treatment of opioid-induced constipation (OIC) in patients with non-cancer-related pain.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid-Induced Constipation (OIC)
Keywords
Non-Cancer-Related Pain, Opioid-Induced Constipation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
844 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Oral Treatment
Arm Title
2
Arm Type
Active Comparator
Arm Description
Oral treatment
Intervention Type
Drug
Intervention Name(s)
NKTR-118
Intervention Description
25 mg oral tablet once daily
Intervention Type
Drug
Intervention Name(s)
Usual care
Intervention Description
As prescribed by the investigator
Primary Outcome Measure Information:
Title
Incidence of Patients Experiencing at Least One Adverse Event (AE)
Description
The incidence of patients experiencing at least one AE during the randomized treatment and follow-up periods was calculated.
Time Frame
Baseline (Week 0) to end of the follow-up period
Title
Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)
Description
The incidence of patients experiencing AEs that resulted in discontinuation of IP during the randomized treatment or follow-up periods was calculated.
Time Frame
Baseline (Week 0) to end of the follow-up period
Title
Incidence of Patients Experiencing Severe Adverse Events (SAEs)
Description
The incidence of patients experiencing SAEs during the randomized treatment and follow-up periods was calculated.
Time Frame
Baseline (Week 0) to end of the follow-up period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
84 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provision of written informed consent prior to any study-specific procedures. NEW PATIENTS ONLY: Self-reported active symptoms of OIC at screening (<3 SBMs/week and experiencing >1 reported symptom of hard/lumpy stools, straining, or sensation of incomplete evacuation/anorectal obstruction in at least 25% of the BMs over the previous 4 weeks); and Documented confirmed OIC (<3 SBMs/week on average over the 2-week OIC confirmation period. PATIENTS ENROLLING FROM OTHER NKTR-118 STUDIES: Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg or oral morphine, or equianalgesic amount(s) of 1 or more opioid therapies. FOR PATIENTS RANDOMIZED TO RECEIVE NKTR-118: Willingness to stop all laxatives and other bowel regimens including prune juice and herbal products throughout the 52-week treatment period, and to use only bisacodyl as rescue medication if BM has not occurred within at least 72 hours of the last recorded BM. Exclusion Criteria: Patients receiving Opioid regimen for treatment of pain related to cancer. History of cancer within 5 years from first study visit with the exception of basal cell cancer and squamous cell skin cancer. Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation. Other issues related to the gastrointestinal tract that could impose a risk to the patient. Pregnancy or lactation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Sostek
Organizational Affiliation
AstraZeneca
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Athens
State/Province
Alabama
Country
United States
Facility Name
Research Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
Research Site
City
Huntsville
State/Province
Alabama
Country
United States
Facility Name
Research Site
City
Mobile
State/Province
Alabama
Country
United States
Facility Name
Research Site
City
Pell City
State/Province
Alabama
Country
United States
Facility Name
Research Site
City
Garden Grove
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Goodyear
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Mesa
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Phoenix
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Tuscon
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Jonesboro
State/Province
Arkansas
Country
United States
Facility Name
Research Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
Research Site
City
North Little Rock
State/Province
Arkansas
Country
United States
Facility Name
Research Site
City
Sherwood
State/Province
Arkansas
Country
United States
Facility Name
Research Site
City
Arcadia
State/Province
California
Country
United States
Facility Name
Research Site
City
Chino
State/Province
California
Country
United States
Facility Name
Research Site
City
Encino
State/Province
California
Country
United States
Facility Name
Research Site
City
Fremont
State/Province
California
Country
United States
Facility Name
Research Site
City
Garden Grove
State/Province
California
Country
United States
Facility Name
Research Site
City
Huntington Park
State/Province
California
Country
United States
Facility Name
Research Site
City
La Mesa
State/Province
California
Country
United States
Facility Name
Research Site
City
Laguna Hills
State/Province
California
Country
United States
Facility Name
Research Site
City
Lakewood
State/Province
California
Country
United States
Facility Name
Research Site
City
Long Beach
State/Province
California
Country
United States
Facility Name
Research Site
City
Oceanside
State/Province
California
Country
United States
Facility Name
Research Site
City
Orange
State/Province
California
Country
United States
Facility Name
Research Site
City
Pasadena
State/Province
California
Country
United States
Facility Name
Research Site
City
Riverside
State/Province
California
Country
United States
Facility Name
Research Site
City
San Bernardino
State/Province
California
Country
United States
Facility Name
Research Site
City
San Diego
State/Province
California
Country
United States
Facility Name
Research Site
City
San Francisco
State/Province
California
Country
United States
Facility Name
Research Site
City
Santa Ana
State/Province
California
Country
United States
Facility Name
Research Site
City
Walnut Creek
State/Province
California
Country
United States
Facility Name
Research Site
City
Whittier
State/Province
California
Country
United States
Facility Name
Research Site
City
Colorado Springs
State/Province
Colorado
Country
United States
Facility Name
Research Site
City
Stamford
State/Province
Connecticut
Country
United States
Facility Name
Research Site
City
Boynton Beach
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Bradenton
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Brooksville
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Chiefland
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Clearwater
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Crystal River
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Daytona Beach
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Debary
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Deerfield Beach
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Delray Beach
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Edgewater
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Eustis
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Fort Myers
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Inverness
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Jackson
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Jupiter
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Largo
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Lauderhill
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Naples
State/Province
Florida
Country
United States
Facility Name
Research Site
City
North Miami
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Ocala
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Orange City
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Orlando
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Oviedo
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Pembroke Pines
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Pinellas Park
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Plantation
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Port Orange
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Port St. Lucie
State/Province
Florida
Country
United States
Facility Name
Research Site
City
South Miami
State/Province
Florida
Country
United States
Facility Name
Research Site
City
St. Doral
State/Province
Florida
Country
United States
Facility Name
Research Site
City
St. Petersburg
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Tamarac
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Tampa
State/Province
Florida
Country
United States
Facility Name
Research Site
City
West Palm Beach
State/Province
Florida
Country
United States
Facility Name
Research Site
City
West Palm
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Winter Park
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Alpharetta
State/Province
Georgia
Country
United States
Facility Name
Research Site
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
Research Site
City
Columbus
State/Province
Georgia
Country
United States
Facility Name
Research Site
City
Marietta
State/Province
Georgia
Country
United States
Facility Name
Research Site
City
Suwanee
State/Province
Georgia
Country
United States
Facility Name
Research Site
City
Tucker
State/Province
Georgia
Country
United States
Facility Name
Research Site
City
Boise
State/Province
Idaho
Country
United States
Facility Name
Research Site
City
Bloomington
State/Province
Illinois
Country
United States
Facility Name
Research Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
Research Site
City
Peoria
State/Province
Illinois
Country
United States
Facility Name
Research Site
City
Schaumburg
State/Province
Illinois
Country
United States
Facility Name
Research Site
City
Evansville
State/Province
Indiana
Country
United States
Facility Name
Research Site
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
Research Site
City
Council Bluffs
State/Province
Iowa
Country
United States
Facility Name
Research Site
City
Kansas City
State/Province
Kansas
Country
United States
Facility Name
Research Site
City
Lansing
State/Province
Kansas
Country
United States
Facility Name
Research Site
City
Overland Park
State/Province
Kansas
Country
United States
Facility Name
Research Site
City
Wichita
State/Province
Kansas
Country
United States
Facility Name
Research Site
City
Louisville
State/Province
Kentucky
Country
United States
Facility Name
Research Site
City
New Orleans
State/Province
Louisiana
Country
United States
Facility Name
Research Site
City
Shreveport
State/Province
Louisiana
Country
United States
Facility Name
Research Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Columbia
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Hollywood
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Pikesville
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Reisterstown
State/Province
Maryland
Country
United States
Facility Name
Research Site
City
Watertown
State/Province
Massachusetts
Country
United States
Facility Name
Research Site
City
Calamazoo
State/Province
Michigan
Country
United States
Facility Name
Research Site
City
Traverse City
State/Province
Michigan
Country
United States
Facility Name
Research Site
City
St Louis
State/Province
Missouri
Country
United States
Facility Name
Research Site
City
St. Louis
State/Province
Missouri
Country
United States
Facility Name
Research Site
City
Bellevue
State/Province
Nebraska
Country
United States
Facility Name
Research Site
City
Fremont
State/Province
Nebraska
Country
United States
Facility Name
Research Site
City
Lincoln
State/Province
Nebraska
Country
United States
Facility Name
Research Site
City
Omaha
State/Province
Nebraska
Country
United States
Facility Name
Research Site
City
Henderson
State/Province
Nevada
Country
United States
Facility Name
Research Site
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
Research Site
City
Clifton
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Freehold
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Lumberton
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Toms River
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Voorhees
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Willingboro
State/Province
New Jersey
Country
United States
Facility Name
Research Site
City
Albuquerque
State/Province
New Mexico
Country
United States
Facility Name
Research Site
City
Great Neck
State/Province
New York
Country
United States
Facility Name
Research Site
City
Hartsdale
State/Province
New York
Country
United States
Facility Name
Research Site
City
New York
State/Province
New York
Country
United States
Facility Name
Research Site
City
North Massapequa
State/Province
New York
Country
United States
Facility Name
Research Site
City
Charlotte
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Elkin
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Flat Rock
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Harrisburg
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Mooresville
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Morganton
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Morrisville
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Winston-salem
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Akron
State/Province
Ohio
Country
United States
Facility Name
Research Site
City
Beavercreek
State/Province
Ohio
Country
United States
Facility Name
Research Site
City
Centerville
State/Province
Ohio
Country
United States
Facility Name
Research Site
City
Toledo
State/Province
Ohio
Country
United States
Facility Name
Research Site
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
Research Site
City
Downingtown
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Jenkintown
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Norristown
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Pottstown
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site
City
Anderson
State/Province
South Carolina
Country
United States
Facility Name
Research Site
City
Charleston
State/Province
South Carolina
Country
United States
Facility Name
Research Site
City
Greer
State/Province
South Carolina
Country
United States
Facility Name
Research Site
City
Myrtle Beach
State/Province
South Carolina
Country
United States
Facility Name
Research Site
City
Chattanooga
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Clarksville
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Jackson
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Memphis
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Milan
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
New Tazewell
State/Province
Tennessee
Country
United States
Facility Name
Research Site
City
Austin
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Hurst
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Lexington
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Marshall
State/Province
Texas
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Sugarland
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Victoria
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Clinton
State/Province
Utah
Country
United States
Facility Name
Research Site
City
Ogden
State/Province
Utah
Country
United States
Facility Name
Research Site
City
Saint George
State/Province
Utah
Country
United States
Facility Name
Research Site
City
Salt Lake City
State/Province
Utah
Country
United States
Facility Name
Research Site
City
West Jordan
State/Province
Utah
Country
United States
Facility Name
Research Site
City
Richmond
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Springfield
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Virginia Beach
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Middleton
State/Province
Wisconsin
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
25112584
Citation
Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014 Oct;40(7):771-9. doi: 10.1111/apt.12899. Epub 2014 Aug 12.
Results Reference
derived
Links:
URL
http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1390&filename=Clinical_Study_Report_Synopsis_D3820C00008.pdf
Description
Clinical_Study_Report_Synopsis_D3820C00008

Learn more about this trial

Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

We'll reach out to this number within 24 hrs